-$0.48 EPS Expected for Assembly Biosciences, Inc. (NASDAQ:ASMB) This Quarter

Wall Street analysts predict that Assembly Biosciences, Inc. (NASDAQ:ASMB – Get Rating) will report earnings of ($0.48) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Assembly Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.57) and the highest estimate coming in at ($0.34). Assembly Biosciences posted earnings per share of ($0.55) in the same quarter last year, which would indicate a positive year over year growth rate of 12.7%. The firm is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Assembly Biosciences will report full year earnings of ($2.00) per share for the current year, with EPS estimates ranging from ($2.31) to ($1.42). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.61) per share, with EPS estimates ranging from ($1.76) to ($1.49). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB – Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.48) EPS for the quarter, hitting analysts’ consensus estimates of ($0.48).

A number of equities analysts have commented on the company. StockNews.com assumed coverage on Assembly Biosciences in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Truist Financial reduced their price objective on Assembly Biosciences from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, April 1st. Finally, Mizuho initiated coverage on Assembly Biosciences in a research report on Tuesday, March 22nd. They set a “buy” rating and a $14.00 target price for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $7.02.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its holdings in Assembly Biosciences by 15,633.0% in the first quarter. JPMorgan Chase & Co. now owns 14,789 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 14,695 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Assembly Biosciences in the fourth quarter worth about $31,000. Royal Bank of Canada increased its holdings in shares of Assembly Biosciences by 185.4% in the second quarter. Royal Bank of Canada now owns 10,319 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 6,703 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of Assembly Biosciences by 89.1% in the fourth quarter. Cubist Systematic Strategies LLC now owns 35,654 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 16,800 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Assembly Biosciences in the fourth quarter worth about $83,000. Institutional investors and hedge funds own 52.63% of the company’s stock.

Assembly Biosciences stock opened at $1.54 on Friday. The firm has a market cap of $74.10 million, a P/E ratio of -0.51 and a beta of 0.88. The business’s fifty day moving average is $1.88 and its two-hundred day moving average is $2.05. Assembly Biosciences has a 52 week low of $1.32 and a 52 week high of $4.69.

About Assembly Biosciences (Get Rating)

Assembly Biosciences, Inc, a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.

Further Reading